The field of genetics and its applications continue to evolve rapidly with the publication of multiple genome-wide association studies, the availability of new DNA sequencing technologies, and examples of biomarkers that are being used to help define patient response in myriad diseases (eg, oncology, HIV, autoimmune, cardiovascular). In addition, the increased pressure to demonstrate value of medicines is refocusing efforts and attention on how to effectively and practically define patients who are grouped by biomarkers during and following clinical development. 
Who Should Attend
Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association.
Speakers and agenda are subject to change without notice.
Recording of any DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA. This session will discuss strategies for sample collection that will result in the development of industry best practices for optimal sample collection to improve pharmacogenomic data collection. 
S. Food and Drug Administration
In contrast to Workshop 1, this session will focus on the situation where both the diagnostic test and the drug product are co-developed (ie, companion diagnostics) by a single sponsor or several sponsors in collaboration with each other. It will emphasize efficacy pharmacogenomics where a diagnostic test is intended to optimize the benefit-to-risk ratio of the drug or differentiate it commercially in the marketplace. It will focus on cases outside the area of oncology. Questions to be addressed include: strategic approaches to generating the necessary evidence to satisfy regulatory expectations for both test and medicine, bridging the evidence gap between a research diagnostic and a market-ready diagnostic and challenges inherent in getting healthcare providers to adopt the new test-drug combination and insurers to reimburse for the value added. The session will focus on the situation where the development of a diagnostic test takes place independently from the development and registration of a drug which may be marketed by one or many sponsors. It will emphasize safety pharmacogenomics where relabeling of a previously approved drug with a diagnostic test occurs in order to improve the benefit-to-risk ratio of the drug. Questions to be addressed include: how the quality and quantity of evidence triggers a decision to add a diagnostic to the label, the rationale for label language and the placement of diagnostic test data in the label, the conflict between drug and device regulations which create challenges for relabeling and how healthcare providers react to and adopt label recommendations into their clinical practice and standards of care for treating individual patients. This session will place in context the current problems of sample collection with respect to pharmacogenomic clinical studies and examine the regulatory, clinical, ethical and societal issues. A case study will be introduces that frames the issues, identifies the causes of convenience sampling, and the consequences to clinical trial outcomes. 
Scott D. Patterson, PhD
Different kinds of study designs have been used for pharmacogenomic analyses from retrospective studies to meta-analyses to prospective patient selection for clinical trials. Different study designs will develop different degrees of confidence in evidence for different purposes. This track will examine two case studies and discussion will aim to synthesize different points of view to enable the development of a 'principles' document on fit for purpose study design. 
